Abstract

Recombinant adeno-associated viral vectors (rAAV) represent a gene therapy tool of ever-increasing importance. Their utilization as a delivery vehicle for gene replacement, silencing and editing, among other purposes, demonstrate considerable versatility. Emerging vector utilization in various experimental, preclinical and clinical applications establishes the necessity of producing and characterizing a wide variety of rAAV preparations. Critically important characteristics concerning quality control are rAAV titer quantification and the detection of impurities. Differences in rAAV constructs necessitate the development of highly standardized quantification assays to make direct comparisons of different preparations in terms of assembly or purification efficiency, as well as experimental or therapeutic dosages. The development of universal methods for impurities quantification is rather complicated, since variable production platforms are utilized for rAAV assembly. However, general agreements also should be achieved to address this issue. The majority of methods for rAAV quantification and quality control are based on PCR techniques. Despite the progress made, increasing evidence concerning high variability in titration assays indicates poor standardization of the methods undertaken to date. This review summarizes successes in the field of rAAV quality control and emphasizes ongoing challenges in PCR applications for rAAV characterization. General considerations regarding possible solutions are also provided.

Highlights

  • Recombinant adeno-associated virus is an increasingly important gene therapy vector

  • We focus on PCR-based methods for Recombinant adeno-associated virus (rAAV) quality control (QC)

  • Two remaining alternative open reading frames (ORFs) are presented by assembly activating protein (AAP) and recently discovered membrane-associated accessory protein (MAAP) encoding genes

Read more

Summary

Introduction

Recombinant adeno-associated virus (rAAV) is an increasingly important gene therapy vector. Three AAV-based therapies have been approved for medical application: Glybera (alipogene tiparvovec, discontinued), Luxturna (voretigene neparvovec) and Zolgensma (onasemnogene abeparvovec) These products utilize rAAV serotypes 1, 2 and 9 for the delivery of a functional gene copy. Gene delivery by viral vector can either compensate for a malfunctioning gene (gene replacement therapy) or provide a new function to help fight a disease (gene addition therapy) These gene therapy approaches are being tested in more than 200 clinical trials [3]. Wide characterization of rAAV preparations provide information about quantity, identity, stability, functionality and presence of substances that may potentially interfere with successful vector administration [11] The majority of these parameters can be qualified using PCR, which is widely used in laboratories all around the world. Recommendations for the sufficient characterization of rAAV preparations based on a complex approach and future perspectives are provided in Sections 6 and 7

AAV Biology
AAV Production
Methods of AAV Quantitation
Quantitative Real-Time PCR
Primer Selection
Protocol Modifications
Calibration Curve
Reference Material
Droplet Digital PCR
Other Methods for Genome Copy Number Measurement
DNA Impurities
Complex QC Analysis of rAAV Preparations
Future Perspectives
Methods
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call